Download Eisai Corporate Factsheet

Eisai Corporate Factsheet
History
1941: Eisai founded in Japan
1961: Listed on the Toyko stock exchange
1970: Eisai establishes its first Asian operation in Indonesia
1981: Eisai establishes its North American operation in California
1988: European operations established
1990: Eisai establishes a UK R&D operation, Eisai London Research Laboratories at
University College London.
1993: Eisai introduces the corporate philosophy of hhc (the Human Health Care)
1997: Aricept® (donepezil hydrochloride) the leading treatment for Alzheimer’s disease
first launched (USA)
1997: Pariet® (rabeprazole sodium) a proton pump inhibitor (PPI) used in the treatment
of gastro-intestinal disorders first launched (Japan)
2001: First Environmental and Social Report published
2004: European Regional HQ established (London)
2005: Eisai started marketing Zonegran® (zonisamide) in the U.S.
2006: Plans announced for a strategic European base in UK
Company Information
Eisai employs more than 8,000 people worldwide and operates in over 30 countries
including the UK, Germany, France, Spain, Italy, Switzerland, Sweden, Austria, Ireland,
USA, Taiwan, China, Korea, India, plus its home market of Japan.
Eisai is ranked amongst the world’s top 20 pharmaceutical companies with group sales of
£2.6 billion. More than 50% of group sales are derived from outside Japan.
Focuses its research efforts in three therapeutic areas: neurology, gastro-intestinal
disorders and oncology/critical care.
Eisai is the company behind the well known drug brands Aricept® (donepezil
hydrochloride) used in the treatment of Alzheimer’s disease, Pariet® (rabeprazole) a
proton pump inhibitor (PPI) used in the treatment of gastro-intestinal disorders and
Zonegran® (zonisamide) for the treatment of epilepsy.
Eisai plans to bring a number of new products to market in the coming years including
potential new treatment for Alzheimer’s Disease, Parkinson’s, epilepsy, multiple sclerosis,
and migraine prophylaxis. The company also has several novel cancer treatments in
clinical development.
For further information visit
www.eisai.co.jp